- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04459936
Urica Cor Intervention (URICORI) Trial (URICORI)
A Multifactorial 'Urica Cor Intervention' to Prevent Cardiovascular Disease in People With Gout: Protocol for the Multicentre, Randomised Controlled, Blinded Endpoint URICORI Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Introduction: Gout has been associated with a number of comorbidities including cardiovascular disease (CVD). Mounting evidence suggests that hyperuricaemia and gout are associated with a high risk for CVD. Gout is closely related to hypertension, dyslipidaemia, obesity and metabolic syndrome, all well-known factors contributing to the development of CVD. Gout management guidelines all agree that comorbidity screening is relevant and thus should be implemented in contemporary gout management. However, no specific strategy for management of CVD risk factors, in a gout population, exists.
Objective: The objective of the Urica Cor Intervention (URICORI) trial is to evaluate the effectiveness of a one-year, intervention of modifiable risk factors for CVD administered in a rheumatology outpatient clinical setting, compared with conventional treatment for modifiable risk factors for CVD in people with gout.
Design: The study is a randomised, open label, blinded endpoint trial, with balanced randomisation (1:1) conducted in four rheumatology outpatient clinics in Denmark. The investigators aim to recruit 266 people with gout, fulfilling the current EULAR ( European League against Rheumatism)/ ACR (American College of Rheumatology) gout classification criteria. Eligible patients will be randomised to receive either conventional (control group) treatment for CVD risk factors administered by their general practitioner according to national guidelines (NG) versus the URICORI programme, administered at the rheumatology department, targeting the same CVD risk factors according to NG. Both groups will be treated for gout at their local department of rheumatology.
End Points: primary end point is a composite endpoint. By inclusion in the URICORI programme all participants will be considered a member of one of four categories derived from the Systematic Coronary Risk Estimation (SCORE) screening programme designed to assess the 10 year risk of fatal cardiovascular disease in European low risk population. As a consequence, participants will be classified as responder after 12 months if all national treatment targets for LDL cholesterol, HbA1c, Blood pressure (systolic and diastolic), according to their SCORE risk profile, is met and no commencement of smoking. If not, participants will be classified as non-responders.
Key secondary end points: Change from baseline of LDL cholesterol, HbA1c, systolic blood pressure, diastolic blood pressure, smoking status and change from baseline in serum urate. Exploratory end points: Proportion of participants achieving treatment target for LDL cholesterol, HbA1c, systolic blood pressure, diastolic blood pressure, change in smoking status (commencement and cessation) and proportion of participants achieving serum urate < 36.0 mmol/l or serum urate < 0.30 mmol/l for tophaceous disease.
After year 1 and year 5, the first occurrence of any serious cardiovascular event (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or urgent revascularization due to unstable angina) during the URICORI trial will be registered. Death and hospitalisation during the URICORI trial will also be evaluated after year 5. Events will be determined by medical record review and evaluated by the endpoint adjudication committee. The Outcome Measures in Rheumatology (OMERACT) endorsed Core Domain Set for us in trials in gout will measured during and after the one-year URICORI intervention trial.
Ethics and dissemination: The local ethics committee in the region of southern Denmark and the Danish data agency in the region of southern Denmark will approve this protocol prior to commencement.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Odense, Denmark, 5000
- Odense University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gout according to current EULAR/ACR (American College of Rheumatology) gout classification criteria
- Age >18 years
- Plasma LDL >3.0 mmol/L
- Agreeable to start treatment for CVD risk factors if indicated
- Ability to give informed consent
- Ability to communicate via telephone
Exclusion Criteria:
- Other inflammatory diseases requiring immunosuppressant therapy.
- Age >70 years.
- Active cancer (in active treatment).
- Chronic kidney disease (eGFR <30 ml/min/1.73m2).
- People whose behaviour or lifestyle would render them less likely to comply with the study protocol (i.e., abuse of alcohol, substance misuse or debilitating psychiatric conditions).
- Familial hypercholesterolemia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Management by Rheumatologist
Treatment of modifiable risk factors for cardiovascular disease managed by the Rheumatologist according to national guideline.
|
Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology
|
Active Comparator: Management by General Practitioner
Treatment of modifiable risk factors for cardiovascular disease managed by the General Practitioner according to national guideline.
|
Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Responders (Dichotomised: responder/non-responder)
Time Frame: 1 year from inclusion
|
Primary end point is a composite endpoint.
By inclusion in the URICORI trial all participants will be considered a member of one of four categories derived from the Systematic Coronary Risk Estimation (SCORE - screening programme designed to assess the 10 year risk of fatal cardiovascular disease in European low risk population, range 0-24%).
As a consequence, participants will be classified as responder after 12 months if all national treatment targets for LDL cholesterol, HbA1c, Blood pressure (systolic and diastolic), according to their SCORE risk profile, is met and no commencement of smoking.
If not, participants will be classified as non-responders.
|
1 year from inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL Cholesterol
Time Frame: 1 year from inclusion
|
Change from baseline of LDL Cholesterol (mmol/L)
|
1 year from inclusion
|
HbA1c
Time Frame: 1 year from inclusion
|
Change from baseline of HbA1c (mmol/mol).
|
1 year from inclusion
|
Systolic blood pressure
Time Frame: 1 year from inclusion
|
Change from baseline Systolic blood pressure (mmHg).
|
1 year from inclusion
|
Diastolic blood pressure Change from baseline Diastolic blood pressure (mmHg).
Time Frame: 1 year from inclusion
|
Change from baseline Diastolic blood pressure (mmHg)
|
1 year from inclusion
|
Smoking
Time Frame: 1 year from inclusion
|
Change in smoking status (dichotomised yes/no)
|
1 year from inclusion
|
Serum Urate
Time Frame: 1 year from inclusion
|
Change from baseline in serum urate (mmol/L)
|
1 year from inclusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL cholesterol
Time Frame: 1 and 5 years from inclusion
|
Proportion of participants achieving treatment target for LDL cholesterol (mmol/L)
|
1 and 5 years from inclusion
|
HbA1c
Time Frame: 1 and 5 years from inclusion
|
Proportion of participants achieving HbA1c (mmol/mol) treatment target.
|
1 and 5 years from inclusion
|
Systolic blood pressure
Time Frame: 1 and 5 years from inclusion
|
Proportion of participants achieving treatment target for systolic blood pressure (mmHg)
|
1 and 5 years from inclusion
|
Diastolic blood pressure
Time Frame: 1 and 5 years from inclusion
|
Proportion of participants achieving treatment target for diastolic blood pressure (mmHg)
|
1 and 5 years from inclusion
|
Smoking
Time Frame: 1 and 5 years from inclusion
|
Proportion of participants with change in smoking status (commencement and cessation)
|
1 and 5 years from inclusion
|
Serum urate
Time Frame: 1 and 5 years from inclusion
|
Proportion of participants achieving serum urate < 36.0 mmol/l or if tophaceous disease serum urate < 0.30 mmol/l
|
1 and 5 years from inclusion
|
Cardiovascular event
Time Frame: 1 year form inclusion
|
Proportion of participants with any serious cardiovascular event during the first year of the URICORI trial.
|
1 year form inclusion
|
Serious cardiovascular event
Time Frame: 5 years from inclusion
|
Proportion of patients with any serious cardiovascular event during the 5-year URICORI trial.
(serious cardiovascular event: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or urgent revascularization due to unstable angina)
|
5 years from inclusion
|
Death
Time Frame: 5 years from inclusion
|
Death from any cause (death will be classified as due to either cardiovascular or non-cardiovascular)
|
5 years from inclusion
|
Hospitalisation
Time Frame: 5 years from inclusion
|
Hospitalisation due to elective or acute cardiovascular reasons during the URICORI trial.
|
5 years from inclusion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Melanie Morillon, MD, Odense University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OL10224607
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted